Celldex Therapeutics Logo
US15117B2025
A2PEAB
CLDX

Celldex Therapeutics

Previsioni

Il prezzo obiettivo medio degli analisti è 60,88 € (+143,52%). La mediana è 56,96 € (+127,84%).

Acquista
  18
Mantieni
  2
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Celldex puts Barzolvolimab in the spotlight – pivotal Phase‑III data expected by end of 2026

    At the Cantor conference, Celldex presented Barzolvolimab as its lead candidate for chronic spontaneous urticaria (CSU), highlighting strong Phase‑II results (65% angioedema‑free patients vs. 25% for placebo) and a large Phase‑III program enrolling nearly 2,000 patients. CSU data are expected by the end of 2026; the readout will determine commercial prospects and whether other projects such as CDX‑622 and atopic dermatitis studies will continue. Management emphasized a consistent safety profile in about 700 patients treated so far and the potential for a premium‑pricing strategy based on durable efficacy; no financial figures were disclosed. » Altro su de.investing.com


  • Celldex Therapeutics reaches 52-week high at $40.30

    Celldex Therapeutics’ stock rose to a 52-week high of $40.30, giving it a market capitalization of about $3.16 billion; the share has gained 73% over six months and 86.85% year to date. InvestingPro currently rates the stock as overvalued versus its fair value. At the same time, Celldex has discontinued the Phase II study of barzolvolimab in prurigo nodularis after failing to meet the primary and key secondary endpoints, prompting differing analyst price targets (Canaccord slightly lowered, Guggenheim raised, UBS reiterated). Chief Financial Officer Sam Martin announced he will retire in March 2027. » Altro su de.investing.com


  • Celldex shares fall after failed phase‑2 trial of barzolvolimab

    Celldex reported that the phase‑2 trial of barzolvolimab in prurigo nodularis did not meet the primary and key secondary endpoints, sending the stock sharply lower in after‑hours trading. Barzolvolimab markedly reduced mast cells and serum tryptase but showed no significant improvement in itch or skin lesions versus placebo. Celldex is discontinuing the prurigo nodularis study, emphasizes a favorable safety profile, and will continue developing barzolvolimab in other indications; Phase‑3 topline data for chronic spontaneous urticaria are expected in Sep/Oct 2026. » Altro su de.investing.com


  • Celldex Therapeutics hits 52-week high at $39.16

    Shares of Celldex Therapeutics climbed to a new 52-week high of $39.16, having nearly doubled from a low of $19.72 and bringing market capitalization to about $3.07 billion. Investor confidence is supported by positive clinical data, including promising Phase 1 results for CDX-622 and continued improvements with barzolvolimab in angioedema. Several analysts raised their valuations or maintained buy ratings (UBS: Buy; Wells Fargo: Overweight with a $54 target; Barclays: upgraded to Overweight), while InvestingPro rates the stock as overvalued relative to its fair value. » Altro su de.investing.com


  • Celldex Therapeutics posts durable Phase 2 barzolvolimab data, supports potential 2027 CSU approval

    Celldex reported updated Phase 2 findings showing barzolvolimab produced rapid, sustained improvements in angioedema and chronic spontaneous urticaria symptoms, with benefits evident seven months after dosing. UBS raised its price target and kept a Buy rating, citing a favorable Phase 3 outlook that could enable approval in 2027. The data bolster barzolvolimab’s potential to move CSU treatment toward disease modification and support continued Phase 3 evaluation. » Altro su finance.yahoo.com

Dati finanziari

Nell'ultimo trimestre, Celldex Therapeutics ha registrato ricavi pari a 0 € e un utile netto di -66,71 Mln €

(EUR) settembre 2026
YoY
Ricavi 0 -
Utile lordo 0 100,00%
Utile netto -66,71 Mln 16,76%
EBITDA -65,68 Mln 16,40%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
1,96 Mld €
Numero di azioni
78,55 Mln
Massimo/minimo a 52 settimane
41,14 € - 20,35 €
Dividendi No
Beta
0,90
Rapporto P/E
-6,36
Rapporto PEG
0,26
Rapporto P/B
3,32
Rapporto P/S
19.229,51

Profilo aziendale

Celldex Therapeutics, Inc., una società biofarmaceutica, si occupa dello sviluppo di anticorpi monoclonali terapeutici e anticorpi bispecifici per il trattamento di diverse malattie. I suoi candidati farmaco includono terapie a base di anticorpi per curare pazienti affetti da malattie infiammatorie e varie forme di cancro. I programmi di sviluppo clinico dell'azienda comprendono CDX-0159, un anticorpo monoclonale in Fase I che si lega al recettore tirosin-chinasico KIT e ne inibisce l'attività; CDX-1140, un anticorpo monoclonale umano agonista diretto contro CD40, un importante attivatore della risposta immunitaria, presente su cellule dendritiche, macrofagi e linfociti B, nonché espresso su varie cellule tumorali; e CDX-527, un anticorpo bispecifico che utilizza gli anticorpi umani proprietari attivi anti-PD-L1 e anti-CD27 dell'azienda per accoppiare la costimolazione di CD27 con il blocco della via PD-L1/PD-1, contribuendo a innescare e attivare le risposte antitumorali delle cellule T attraverso la costimolazione di CD27. La società ha accordi di collaborazione nella ricerca e di licenza con la University of Southampton per lo sviluppo di anticorpi umani diretti contro CD27; con Amgen Inc., che detiene diritti esclusivi su CDX-301 e sul ligando di CD40; e con la Yale University. Celldex Therapeutics, Inc. è stata costituita nel 1983 ed ha sede a Hampton, nel New Jersey.

Nome
Celldex Therapeutics
CEO
Anthony S. Marucci
Sede centrale Hampton, nj
Stati Uniti
Sito web
Settore
Sanità
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
15/05/1986
Dipendenti 198

Simboli di borsa

Borsa Simbolo
NASDAQ
CLDX
Frankfurt
TCE2.F
Düsseldorf
TCE2.DU
SIX
TCE1.SW
München
TCE2.MU
🍪

Parqet  usa i cookie. Scopri di più